Biohaven advances development of the mode platform technology licensed from yale university

Biohaven advances development of its extracellular target degrader platform technology (modes™) for therapies across a variety of diseases including neuroscience, immunology and oncology through its continued collaboration with yale university in the laboratory of professor david spiegel and biohaven labs, biohaven has made further innovations in this ground-breaking technology with new patent applications covering additional targets and functionality in-licensed from yale university in 2021, the mode platform is based on patent applications filed by yale in 2018 and 2019 new haven, conn. , oct. 25, 2022 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking